$--
(Market cap
--
Revenue (TTM)
--
P/E Ratio
--
P/B Ratio
--
Div. Yield
--
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
--
-
ROE
--
-
ROCE
--
-
Industry P/E
--
-
EV/EBITDA
--
-
Debt to Equity
--
-
Book Value
--
-
EPS
--
-
Face value
--
-
Shares outstanding
--
Years Aggregate
CFO
$--
EBITDA
$--
Net Profit
$--
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Notable Labs, (NTBLQ)
| -99.0 | -- | -- | -99.0 | -99.5 | -97.3 | -84.7 |
|
BSE Sensex*
| -9.2 | -1.3 | 2.8 | -3.7 | 5.7 | 6.2 | 10.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
|---|---|
|
Notable Labs, (NTBLQ)
| -99.6 |
|
S&P Small-Cap 600
| 4.0 |
|
BSE Sensex
| 9.1 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout Notable Labs, (NTBLQ)
Notable Labs, Ltd., a clinical-stage platform therapeutics company, develops predictive medicines for patients with cancer. The company, through its proprietary Predictive Medicines Platform (PMP), bio-simulates a patient's cancer treatment and... predicts whether patient will clinically respond to their actual treatment. Its PMP is designed to identify and select patients expected to be clinically responsive prior to the initiation of their treatment and enable fast-track therapeutic development in this patient population. The company's lead product is Volasertib, a polo like kinase 1 inhibitor to induce cell cycle arrest and apoptosis in various cancer cells. It is also developing two candidate predictive medicines and clinical-stage candidates for development in platform-predicted responders with acute myeloid leukemia. The company is based in Foster City, California. On October 13, 2024, Notable Labs, Ltd. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware. Read more
-
Chief Financial Officer
Mr. Scott Alan McPherson CFE, CPA, CVA
-
Chief Scientific Officer
Dr. Joseph P. Wagner Ph.D.
-
Headquarters
Foster City, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Notable Labs, (NTBLQ)
What is the current share price of Notable Labs, Ltd (NTBLQ) Today?
The share price of Notable Labs, Ltd (NTBLQ) is $0.00 (NASDAQ) as of 11-Aug-2026 14:49 EDT. Notable Labs, Ltd (NTBLQ) has given a return of -99.51% in the last 3 years.
What is the current PB & PE ratio of Notable Labs, Ltd (NTBLQ)?
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2023 |
-- |
-- |
2022 |
-- |
-- |
2021 |
-- |
-- |
2023 |
-- |
-- |
2022 |
-- |
-- |
What is the 52 Week High and Low of Notable Labs, Ltd (NTBLQ)?
The 52-week high and low of Notable Labs, Ltd (NTBLQ) are Rs 0.00 and Rs 0.00 as of 31-Aug-2026.
What is the market cap of Notable Labs, Ltd (NTBLQ)?
Notable Labs, Ltd (NTBLQ) has a market capitalisation of $ 0 Mln as on 21-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Notable Labs, Ltd (NTBLQ)?
Before investing in Notable Labs, Ltd (NTBLQ), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.